Accede al análisis completo con tu suscripción
Últimos 20 reportes · 10-K · 10-K/A · 10-Q · 8-K · Fuente: SEC EDGAR
Accede al análisis completo con tu suscripción
SEC CIK: 0001964738
Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise. Our 70+ year history of discovering and innovating advanced solutions has helped us solve our customers’ toughest challenges. Our solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and accuracy. Additionally, our products and services are present along a patient’s journey through prevention, diagnosis, treatment, and recovery. Our business possesses strong customer relationships, a broad, wide-ranging, and well-known portfolio of brands, differentiated technology, and manufacturing expertise.
Ver másPrecio actual · USD
$91.12
Consenso de Analistas
Precio Objetivo — 12 meses
$70.00
Mínimo
-23.2%
$95.00
Mediana
+4.3%
$93.92
Promedio
+3.1%
$113.00
Máximo
+24.0%
P/E LTM
11.14
Precio / EPS LTM diluido
ROIC (NOPAT / IC)
17.8%
NOPAT / (Equity + Debt)
R&D / Revenue
8.7%
R&D / Ingresos
Gross Margin
54.7%
Gross profit / Ingresos
ROE (avg equity)
29.1%
Benef. neto / Patrimonio
ROA (avg assets)
10.1%
Benef. neto / Activo total
Operating Margin
25.0%
Op. income / Ingresos
Margen Neto
17.3%
Benef. neto / Ingresos
| Métrica | LTM jun 26 | 2025 | 2024 | 2023 | 🔒Premium |
|---|---|---|---|---|---|
| INGRESOS Y MÁRGENES | |||||
| Ingresos Totales | 8.310B | 8.325B | 8.254B | 8.197B | 🔒 |
| Gross Profit | 4.544B | 4.451B | 4.593B | 4.693B | 🔒 |
| Gross Margin | 54.7% | 53.5% | 55.6% | 57.3% | 🔒 |
| I+D Y GASTOS OPERATIVOS | |||||
| R&D | 725.000M | 739.000M | 775.000M | 758.000M | 🔒 |
| R&D / Revenue | 8.7% | 8.9% | 9.4% | 9.3% | 🔒 |
| SG&A | 3.293B | 3.080B | 2.782B | 2.299B | 🔒 |
| Depreciación & Amort. | 506.000M | 489.000M | |||
| STOCK-BASED COMPENSATION | |||||
| Stock-Based Compensation | 167.000M | 161.000M | 112.000M | 39.000M | 🔒 |
| SBC / Revenue | 2.0% | 1.9% | 1.4% | 0.5% | 🔒 |
| RESULTADO NETO | |||||
| Pretax Income | 1.695B | 1.713B | 605.000M | 1.667B | 🔒 |
| Interest Expense (P&L) | 265.000M | — | — | — | 🔒 |
| Tax Expense | 262.000M | 157.000M | 127.000M | 321.000M | 🔒 |
| Beneficio Neto | 1.434B | 1.556B | |||
| INVENTARIO | |||||
| Inventario Neto | 1.040B | 1.066B | 965.000M | 857.000M | 🔒 |
| LIQUIDEZ E INVERSIONES | |||||
| Cash & Equivalentes | 403.000M | 878.000M | 762.000M | 194.000M | 🔒 |
| Total Liquid Assets | 403.000M | 878.000M | 762.000M | 194.000M | 🔒 |
| BALANCE — ACTIVOS | |||||
| PP&E Neto | 1.326B | 1.326B | 1.622B | 1.457B | 🔒 |
| Goodwill | 5.626B | 5.704B | 6.377B | 6.535B | 🔒 |
| Intangibles | 2.408B | 2.592B | 2.544B | 2.902B | 🔒 |
| Activo Total | 14.243B | 14.294B | |||
| CAPITAL Y DEUDA | |||||
| Deuda Total | 5.079B | 5.035B | 8.010B | 0.00 | 🔒 |
| Net Debt | 4.676B | 4.157B | 7.248B | -194.000M | 🔒 |
| Patrimonio Neto | 4.800B | 5.049B | 2.959B | 11.666B | 🔒 |
| Invested Capital | 9.879B | 10.527B | |||
| FLUJO DE CAJA Y CAPEX | |||||
| Cash Flow Operativo (CFO) | 209.000M | 369.000M | 1.185B | 1.915B | 🔒 |
| Capex | 327.000M | 379.000M | 380.000M | 290.000M | 🔒 |
| Free Cash Flow (FCF) | -118.000M | -10.000M | 805.000M | 1.625B | 🔒 |
| FCF Margin | -1.4% | -0.1% | |||
| RATIOS | |||||
| ROIC (NOPAT / IC) | 17.8% | 18.8% | 7.2% | 11.7% | 🔒 |
| R&D / Revenue | 8.7% | 8.9% | 9.4% | 9.3% | 🔒 |
| Gross Margin | 54.7% | 53.5% | 55.6% | 57.3% | 🔒 |
| ROE (avg equity) | 29.1% | 38.9% | |||
Cifras en miles de millones (B) · Fuente: SEC/EDGAR
| 555.000M |
| 561.000M |
| 🔒 |
| Operating Income | 2.076B | 2.181B | 1.036B | 1.692B | 🔒 |
| Operating Margin | 25.0% | 26.2% | 12.6% | 20.6% | 🔒 |
| 479.000M |
| 1.346B |
| 🔒 |
| Margen Neto | 17.3% | 18.7% | 5.8% | 16.4% | 🔒 |
| EPS Diluido | 8.18 | 8.88 | 2.76 | 7.79 | 🔒 |
| EPS Básico | 8.23 | 8.94 | 2.77 | 7.79 | 🔒 |
| 14.457B |
| 13.943B |
| 🔒 |
| Pasivo Total | 9.443B | 9.245B | 11.498B | 2.277B | 🔒 |
| 11.318B |
| 11.704B |
| 🔒 |
| Acciones en Circulación | 170.224M | 173.491M | 172.786M | 0.00 | 🔒 |
| 9.8% |
| 19.8% |
| 🔒 |
| NOPAT | 1.755B | 1.981B | 818.526M | 1.366B | 🔒 |
| Adquisiciones (Business) | 696.000M | 696.000M | 0.00 | 0.00 | 🔒 |
| 6.5% |
| 11.5% |
| 🔒 |
| ROA (avg assets) | 10.1% | 10.8% | 3.4% | 9.7% | 🔒 |
| Operating Margin | 25.0% | 26.2% | 12.6% | 20.6% | 🔒 |
| Margen Neto | 17.3% | 18.7% | 5.8% | 16.4% | 🔒 |
| FCF Margin | -1.4% | -0.1% | 9.8% | 19.8% | 🔒 |
| Effective Tax Rate | 15.5% | 9.2% | 21.0% | 19.3% | 🔒 |
| Debt / Equity Ratio | 1.06x | 1.00x | 2.71x | 0.00x | 🔒 |